Abstract:Recently, mixed-ligand copper(II) complexes have received much attention in searching for alternative metallodrugs to cisplatin. A series of mixed ligand Cu(II) complexes of the type [Cu(L)(diimine)](ClO4) 1-6, where the HL is 2-formylpyridine-N4-phenylthiosemicarbazone and the diimine is 2,2'-bipyridine (1), 4,4'-dimethyl-2,2'-bipyridine (2), 1,10-phenanthroline (3), 5,6-dimethyl-1,10-phenanathroline (4), 3,4,7,8-tetramethyl-1,10-phenanthroline (5) and dipyrido-[3,2-f:2',3'-h]quinoxaline (6), has been synthesized and their cytotoxicity in HeLa cervical cancer cells examined. In the molecular structures of 2 and 4, as determined by single-crystal X-ray studies, Cu(II) assumes a trigonal bipyramidal distorted square-based pyramidal (TBDSBP) coordination geometry. DFT studies reveal that the axial Cu-N4diimine bond length, interestingly, varies linearly with the experimental CuII/CuI reduction potential as well as the trigonality index τ of the five-coordinate complexes, and that methyl substitution on diimine co-ligands tunes the extent of the Jahn-Teller distortion at the Cu(II). While 4 is involved in strong DNA groove binding with a hydrophobic interaction of methyl substituents, 6 is involved in stronger binding through partial intercalation of dpq with DNA. Complexes 3, 4, 5, and 6 efficiently cleave supercoiled DNA into NC form in ascorbic acid by generating hydroxyl radicals. Interestingly, 4 exhibits higher DNA cleavage in hypoxic than at normoxic conditions. Notably, except for [CuL]+, all the complexes were stable in 0.5% DMSO-RPMI (without phenol red) cell culture medium up to 48 h at 37 °C. Remarkably, all the complexes show time-dependent cytotoxicity at nanomolar concentrations (IC50, 7.0-182 nM) in HeLa cervical cancer cells compared with uncoordinated ligand HL (IC50 > 10 000 nM). Except for 2 and 3, all the complexes exhibit higher cytotoxicity than [CuL]+ at 48 h. 4 shows (57.2 nM) higher cytotoxicity than 1 (181.5 nM) at 24 h incubation; however, notably, 1 demonstrates phenomenal cytotoxicity (7.0 nM) higher than 4 (13.6 nM) at 48 h incubation. The selectivity index (SI) reveals that complexes 1 and 4 are 53.5 and 37.3, respectively, times less toxic to HEK293 normal cells than to cancerous cells. Except for [CuL]+, all the complexes generate ROS to different extents at 24 h, with 1 producing the highest amount, which is consistent with their redox properties. Also, 1 and 4 exhibit, respectively, sub-G1 and G2-M phase cell arrest in the cell cycle. Therefore, complexes 1 and 4 have the potential to emerge as promising anticancer agents.

Mixed Ligand Mononuclear Copper(II) Complex as a Promising Anticancer Agent: Interaction Studies with DNA/HSA, Molecular Docking, and In Vitro Cytotoxicity Studies.

DNA Binding, Crystal Structure, Molecular Docking Studies and Anticancer Activity Evaluation of a Copper(ii) Complex

Mononuclear Copper(II) Complexes with Polypyridyl Ligands: Synthesis, Characterization, DNA Interactions/Cleavages and in vitro Cytotoxicity towards Human Cancer Cells

1‐Benzyl‐1H‐indazol‐3‐ol Copper(II) Derivatives as Anticancer Agents: In‐vitro Interaction with DNA/BSA, DFT, Molecular Docking and Cytotoxicity on MCF7 Cells

Synthesis, Characterization, DNA/HSA Interactions, and Anticancer Activity of Two Novel Copper(II) Complexes with 4-Chloro-3-Nitrobenzoic Acid Ligand

DNA BINDING, IN VITRO CYTOTOXICITY AND ANTICANCER DRUG MECHANISM OF COPPER(II) COMPLEX CONTAINING PYRIDYL-TRIAZINE LIGAND

Mixed‐Ligand Mononuclear Copper(II) Complex: Crystal Structure and Anticancer Activity

Copper(II) complexes incorporated with 2,2-bipyridyl and 2,2′-(((1E,1′E)-1,4-phenylene-bis(methanylylidene))bis(azanylylidene)) diphenol derivatives: In-vitro interaction with DNA/BSA, DFT, molecular docking and cytotoxicity

Copper-Plumbagin Complex Produces Potent Anticancer Effects by Depolymerizing Microtubules and Inducing Reactive Oxygen Species and DNA Damage

Copper(II) complexes containing hydrazone and bipyridine/phenanthroline ligands for anticancer application against breast cancer cells

Mixed ligand copper(II)-diimine complexes of 2-formylpyridine- N4-phenylthiosemicarbazone: diimine co-ligands tune the in vitro nanomolar cytotoxicity

Biological and cytoselective anticancer properties of copper(II)-polypyridyl complexes modulated by auxiliary methylated glycine ligand

A Tetranuclear copper(II) Complex with a Pyridine‐2,6‐dicarboxamide Ligand: Structural and Magnetic Properties and In vitro Antiproliferative Activity Against Human Cancer Cells

A Mixed-Ligand Copper(Ii) Complex That Inhibits Growth And Induces Apoptosis By Dna Targeting In Human Epithelial Cervical Cancer Cells

Structure and Biological Properties of Mixed-Ligand Cu(II) Schiff Base Complexes As Potential Anticancer Agents.

Experimental and molecular modelling demonstration of effective DNA and protein binding as well as anticancer potential of two mononuclear Cu(II) and Co(II) complexes with isothiocyanate and azide as anionic residues

Mixed-Ligand Copper(Ii) Schiff Base Complexes: the Role of the Co-Ligand in Dna Binding, Dna Cleavage, Protein Binding and Cytotoxicity

Anticancer activity and biophysical reactivity of copper complexes of 2-(benzo[d][1,3]dioxol-5-ylmethylene)-N-alkylhydrazinecarbothioamides

A novel copper(II) complex with salicylidene carbohydrazide ligand that promotes oxidative stress and apoptosis in triple negative breast cancer cells

Three Structurally Related Copper Complexes with Two Isomers: DNA/BSA Binding Ability, DNA Cleavage Activity and Excellent Cytotoxicity

Synthesis of novel coumarin nucleus-based DPA drug-like molecular entity: In vitro DNA/Cu(II) binding, DNA cleavage and pro-oxidant mechanism for anticancer action